オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, film coated - excipient ingredients: hypromellose; croscarmellose sodium; lactose monohydrate; macrogol 400; pregelatinised maize starch; titanium dioxide; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; purified talc; colloidal anhydrous silica - hypertension: as monotherapy or for use in combination with other antihypertensives.,angina pectoris: for long-term prophylaxis. glyceryl trinitrate should be employed if necessary for alleviating acute attacks.,confirmed or suspected myocardial infarction.,prevention of migraine.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; hypromellose; magnesium stearate; iron oxide red; croscarmellose sodium; macrogol 400; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; purified talc; pregelatinised maize starch - hypertension: as monotherapy or for use in combination with other antihypertensives.,angina pectoris: for long-term prophylaxis. glyceryl trinitrate should be employed if necessary for alleviating acute attacks.,confirmed or suspected myocardial infarction.,prevention of migraine.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, film coated - excipient ingredients: hypromellose; croscarmellose sodium; lactose monohydrate; macrogol 400; pregelatinised maize starch; titanium dioxide; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; purified talc; colloidal anhydrous silica - hypertension: as monotherapy or for use in combination with other antihypertensives.,angina pectoris: for long-term prophylaxis. glyceryl trinitrate should be employed if necessary for alleviating acute attacks.,confirmed or suspected myocardial infarction.,prevention of migraine.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; hypromellose; magnesium stearate; iron oxide red; croscarmellose sodium; macrogol 400; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; purified talc; pregelatinised maize starch - hypertension: as monotherapy or for use in combination with other antihypertensives.,angina pectoris: for long-term prophylaxis. glyceryl trinitrate should be employed if necessary for alleviating acute attacks.,confirmed or suspected myocardial infarction.,prevention of migraine.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; citric acid monohydrate; magnesium stearate; povidone; purified talc; alginic acid; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; magnesium stearate; povidone; purified talc; hypromellose; citric acid monohydrate; microcrystalline cellulose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; citric acid monohydrate; povidone; microcrystalline cellulose; hypromellose; magnesium stearate; purified talc; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: citric acid monohydrate; microcrystalline cellulose; alginic acid; povidone; hypromellose; magnesium stearate; purified talc; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: magnesium stearate; microcrystalline cellulose; alginic acid; purified talc; citric acid monohydrate; povidone; hypromellose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: citric acid monohydrate; povidone; alginic acid; microcrystalline cellulose; magnesium stearate; purified talc; hypromellose; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.